Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 2c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.32 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Yiren Digital Ltd. (YRD) Reports Q1 Loss of RMB5.64
• American Outdoor Brands (AOUT) Tops Q4 EPS by 14c